---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002883"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:36:46.056790+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC

## Summary
- Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.
- Initiated THIO-104 Phase 3 trial in 3L NSCLC; Phase 2 Part C expansion underway in Asia and Europe.
- Awarded $2.3M NIH grant for Phase 2 trial; raised ~$17.6M in 2025 capital raises with board participation.
- Targeted 2026 milestones: interim efficacy data from Phase 3, completion of Phase 2 Part C, and start of Phase 1 for second-generation molecules.
- Company claims ateganosine is the only telomere-targeting anticancer agent in clinical development globally.

## SEC filing metadata
- accession: 0001493152-26-002883
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226002883/0001493152-26-002883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226002883/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002883
- JSON: https://secwatch.observer/filing/0001493152-26-002883.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.